Top

Published in:

01-06-2010 | Research Article

RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells

Authors: Qin Xu, Xiuming Liu, Yili Cai, Youcheng Yu, Wantao Chen

Published in: Tumor Biology | Issue 3/2010

Abstract

A disintegrin and metalloproteinase 9 (ADAM9) is a type I transmembrane protein that has been associated with cancer development and metastases. Here, we show that ADAM9 is highly expressed in metastatic cancer tissues and in an adenoid cystic carcinoma cell line with a high metastatic potential. Using RNA interference for gene silencing, we show that ADAM9 is essential for in vitro cancer cell proliferation and invasion as well as in vivo cancer metastasis in an experimental murine model of lung metastases. These data indicate that ADAM9 is potentially an important new therapeutic target for the prevention of tumor metastases in adenoid cystic carcinoma.

Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, Vilos GA, et al. Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol. 2005;41:328–35.CrossRefPubMed

Hu K, Li SL, Gan YH, Wang CY, Yu GY. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. Oral Oncol. 2009;45:156–63.CrossRefPubMed

Becherer JD, Blobel CP. Biochemical properties and functions of membrane-anchored metallprotease-disintegrin proteins (ADAMs). Curr Top Dev Biol. 2003;54:101–23.CrossRefPubMed

Duffy MJ, McKiernan E, O'Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res. 2009;15:1140–4.CrossRefPubMed

Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, et al. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 2008;90:369–79.CrossRefPubMed

Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 2005;65:9312–9.CrossRefPubMed

O’Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer. 2003;105:754–61.CrossRefPubMed

Fritzsche FR, Jung M, Tölle A, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol. 2008;54:1097–106.CrossRefPubMed

Huang D, Chen W, Zhang Z, Zhang P, He R, Zhou X, et al. Identification of genes with consistent expression alteration pattern in ACC-2 and ACC-M cells by cDNA array. Chin Med J (Engl). 2003;116:448–52.

10.

Ikeda S, Fujimori M, Shibata S, et al. Combined immunohistochemistry of β-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer. 2006;2:31.CrossRef

11.

Xu Q, Zhang Z, Zhang P, Chen W. Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer. 2008;8:159.CrossRefPubMed

12.

Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550–3.CrossRefPubMed

13.

Cuneo KC, Fu A, Osusky KL, Geng L. Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anticancer Drugs. 2007;18:349–55.CrossRefPubMed

14.

Chen J, Peng H, Ou-Yang X, He X. Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma cells. Melanoma Res. 2008;18:322–9.CrossRefPubMed

15.

Nakashima Y, Yano M, Kobayashi Y, Moriyama S, Sasaki H, Toyama T, et al. Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery. Gene Ther. 2003;10:123–30.CrossRefPubMed

16.

Carl-McGrath S, Lendeckel U, Ebert M, Roessner A, Röcken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol. 2005;26:17–24.PubMed

17.

Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, Röcken C. Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. Cancer Res Clin Oncol. 2005;131:41–8.CrossRef

18.

Zheng X, Jiang F, Katakowski M, et al. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 2007;98:674–84.CrossRefPubMed

19.

Rocks N, Estrella C, Paulissen G, et al. The metalloproteinase ADAM-12 regulates bronchial epithelial cell proliferation and apoptosis. Cell Prolif. 2008;41:988–1001.CrossRefPubMed

20.

Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW, Liu TY. Increase of disintergin metalloprotease 10(ADAM10) expression in oral squamous cell carcinoma. Cancer Lett. 2007;245:33–43.CrossRefPubMed

21.

Fritzsche FR, Wassermann K, Jung M, Tölle A, Kristiansen I, Lein M, et al. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression. BMC Cancer. 2008;8:179–87.CrossRefPubMed

22.

Boelens MC, Kok K, Van der Vlies P, et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer. 2009;66:372–8.CrossRefPubMed

23.

Zigrino P, Mauch C, Fox JW, Nischt R. Adam-9 expression and regulation in human skin melanoma and melanoma cell lines. Int J Cancer. 2005;116:853–9.CrossRefPubMed

24.

Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005;65:4728–38.CrossRefPubMed

25.

Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, et al. Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004;64:4190–6.CrossRefPubMed

Title: RNAi-mediated ADAM9 gene silencing inhibits metastasis of adenoid cystic carcinoma cells
Authors: Qin Xu
Xiuming Liu
Yili Cai
Youcheng Yu
Wantao Chen
Publication date: 01-06-2010
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 3/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-010-0034-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value

Effect of radiation treatment on newly established human breast cancer cell lines MACL-1 and MGSO-3

MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions

Calcineurin promotes proliferation, migration, and invasion of small cell lung cancer

MMP-7 overexpression is an independent prognostic marker in gastric cancer

Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin

Keynote webinar | Spotlight on antibody–drug conjugates in cancer